JP2018514564A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018514564A5 JP2018514564A5 JP2017556853A JP2017556853A JP2018514564A5 JP 2018514564 A5 JP2018514564 A5 JP 2018514564A5 JP 2017556853 A JP2017556853 A JP 2017556853A JP 2017556853 A JP2017556853 A JP 2017556853A JP 2018514564 A5 JP2018514564 A5 JP 2018514564A5
- Authority
- JP
- Japan
- Prior art keywords
- powder
- zolmitriptan
- particles
- powder formulation
- phosphatidyl choline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000843 powder Substances 0.000 claims 47
- 239000000203 mixture Substances 0.000 claims 25
- 238000009472 formulation Methods 0.000 claims 24
- 239000002245 particle Substances 0.000 claims 19
- UTAZCRNOSWWEFR-ZDUSSCGKSA-N zolmitriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1C[C@H]1COC(=O)N1 UTAZCRNOSWWEFR-ZDUSSCGKSA-N 0.000 claims 16
- 229960001360 zolmitriptan Drugs 0.000 claims 16
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 13
- 235000002639 sodium chloride Nutrition 0.000 claims 11
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims 9
- 229960003136 leucine Drugs 0.000 claims 7
- 239000004395 L-leucine Substances 0.000 claims 6
- 235000019454 L-leucine Nutrition 0.000 claims 6
- 150000003904 phospholipids Chemical class 0.000 claims 6
- 239000011780 sodium chloride Substances 0.000 claims 6
- 239000007787 solid Substances 0.000 claims 6
- 229940024606 amino acid Drugs 0.000 claims 5
- 235000001014 amino acid Nutrition 0.000 claims 5
- 150000001413 amino acids Chemical class 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 150000005846 sugar alcohols Chemical class 0.000 claims 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 230000002685 pulmonary effect Effects 0.000 claims 3
- 229960002668 sodium chloride Drugs 0.000 claims 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 229920002774 Maltodextrin Polymers 0.000 claims 2
- 239000005913 Maltodextrin Substances 0.000 claims 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims 2
- 229940035034 maltodextrin Drugs 0.000 claims 2
- 210000002345 respiratory system Anatomy 0.000 claims 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 1
- IJFVSSZAOYLHEE-SSEXGKCCSA-N 1,2-dilauroyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCC IJFVSSZAOYLHEE-SSEXGKCCSA-N 0.000 claims 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- 208000006561 Cluster Headache Diseases 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 1
- 208000018912 cluster headache syndrome Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000010419 fine particle Substances 0.000 claims 1
- 239000012458 free base Substances 0.000 claims 1
- 150000002337 glycosamines Chemical class 0.000 claims 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 1
- 229960000310 isoleucine Drugs 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 1
- 150000008105 phosphatidylcholines Chemical class 0.000 claims 1
- -1 polyglycitol Substances 0.000 claims 1
- 239000001103 potassium chloride Substances 0.000 claims 1
- 235000011164 potassium chloride Nutrition 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 239000001509 sodium citrate Substances 0.000 claims 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims 1
- 235000011083 sodium citrates Nutrition 0.000 claims 1
- 239000001540 sodium lactate Substances 0.000 claims 1
- 229940005581 sodium lactate Drugs 0.000 claims 1
- 235000011088 sodium lactate Nutrition 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 239000004474 valine Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562155910P | 2015-05-01 | 2015-05-01 | |
| US62/155,910 | 2015-05-01 | ||
| PCT/US2016/030219 WO2016179026A1 (en) | 2015-05-01 | 2016-04-29 | Zolmitriptan powders for pulmonary delivery |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018514564A JP2018514564A (ja) | 2018-06-07 |
| JP2018514564A5 true JP2018514564A5 (enExample) | 2019-06-06 |
Family
ID=56027187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017556853A Pending JP2018514564A (ja) | 2015-05-01 | 2016-04-29 | 肺送達用のゾルミトリプタン粉末 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20160317503A1 (enExample) |
| EP (1) | EP3288591A1 (enExample) |
| JP (1) | JP2018514564A (enExample) |
| KR (1) | KR20180002750A (enExample) |
| AU (1) | AU2016257729A1 (enExample) |
| CA (1) | CA2984339A1 (enExample) |
| HK (1) | HK1251998A1 (enExample) |
| MX (1) | MX2017013950A (enExample) |
| WO (1) | WO2016179026A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1254670A1 (zh) * | 2015-07-02 | 2019-07-26 | Civitas Therapeutics, Inc. | 曲普坦粉末用於肺部给药 |
| CA3085943A1 (en) * | 2017-12-21 | 2019-06-27 | Civitas Therapeutics, Inc. | Surfactant formulations for inhalation |
| MX2021005508A (es) * | 2018-11-13 | 2021-09-08 | Civitas Therapeutics Inc | Fórmulaciones y procesos de polinucleótido en polvo respirable para inhalación. |
| PT3962455T (pt) | 2020-05-18 | 2022-10-13 | Orexo Ab | Nova composição farmacêutica para entrega de fármacos |
| EP4236921A1 (en) | 2021-11-25 | 2023-09-06 | Orexo AB | Pharmaceutical composition comprising adrenaline |
| GB202117016D0 (en) | 2021-11-25 | 2022-01-12 | Orexo Ab | New pharmaceutical device |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6613308B2 (en) * | 2000-09-19 | 2003-09-02 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
| US6766799B2 (en) | 2001-04-16 | 2004-07-27 | Advanced Inhalation Research, Inc. | Inhalation device |
| US6848197B2 (en) | 2001-04-18 | 2005-02-01 | Advanced Inhalation Research, Inc. | Control of process humidity to produce large, porous particles |
| ES2718455T3 (es) * | 2002-03-20 | 2019-07-02 | Civitas Therapeutics Inc | Formulaciones terapéuticas sostenidas inhalables |
| US7763280B2 (en) | 2002-11-28 | 2010-07-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Tiotropium containing powder formulation for inhalation |
| US8496002B2 (en) | 2007-06-12 | 2013-07-30 | Civitas Therapeutics, Inc. | Powder inhaler devices |
| US20110077272A1 (en) * | 2008-02-01 | 2011-03-31 | Vectura Limited | Pulmonary formulations of triptans |
| EP2637657B1 (en) * | 2010-11-09 | 2019-05-22 | MannKind Corporation | Composition comprising a serotonin receptor agonist and a diketopiperazine for treating migraines |
| ITMI20130572A1 (it) * | 2013-04-10 | 2014-10-11 | Eratech Srl | Composizione comprendente almeno due polveri secche ottenute per spray dry per aumentare la stabilita' della formulazione |
-
2016
- 2016-04-29 CA CA2984339A patent/CA2984339A1/en not_active Abandoned
- 2016-04-29 WO PCT/US2016/030219 patent/WO2016179026A1/en not_active Ceased
- 2016-04-29 JP JP2017556853A patent/JP2018514564A/ja active Pending
- 2016-04-29 HK HK18111327.1A patent/HK1251998A1/zh unknown
- 2016-04-29 AU AU2016257729A patent/AU2016257729A1/en not_active Abandoned
- 2016-04-29 MX MX2017013950A patent/MX2017013950A/es unknown
- 2016-04-29 US US15/143,131 patent/US20160317503A1/en not_active Abandoned
- 2016-04-29 EP EP16724183.5A patent/EP3288591A1/en not_active Withdrawn
- 2016-04-29 KR KR1020177034671A patent/KR20180002750A/ko not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018514564A5 (enExample) | ||
| CN111249260B (zh) | 包含rpl554的液体吸入制剂 | |
| US20220296559A1 (en) | Composition of a Spray-Dried Powder for Pulmonary Delivery of a Long Acting Neuraminidase Inhibitor (LANI) | |
| JP5111517B2 (ja) | バルガンシクロビルの粉末製剤 | |
| JP6154803B2 (ja) | 膣投与のための迅速溶解性錠剤組成物 | |
| Minne et al. | Optimization of the aerosolization properties of an inhalation dry powder based on selection of excipients | |
| JP2012517987A5 (ja) | 吸入用の医薬組成物のｆｐｄ特性を設定する方法 | |
| ES2525163T3 (es) | Método para preparar composiciones farmacéuticas pretendidas para administración oral que comprenden uno o más ingredientes activos y las composiciones que comprenden los mismos | |
| US20130098357A1 (en) | Cerivastatin to treat pulmonary disorders | |
| DK2698147T3 (en) | Oral film formulation with dapoxetine tadalafil | |
| MX2014001345A (es) | Metodo y formulacion para inhalacion. | |
| PT1296663E (pt) | Administração altamente eficaz de um aerosol de grande massa terapêutica | |
| JP2010503731A (ja) | 肺サーファクタント製剤および粘液クリアランスの促進方法 | |
| JP2016534153A5 (enExample) | ||
| CN101631563B (zh) | 含有流感疫苗的冻干制剂及其制备方法 | |
| JP7021078B2 (ja) | ニコチンをベースとする乾燥粉末製剤のきつさを制御するためのシステムおよび方法 | |
| JP2016532672A5 (enExample) | ||
| KR20150128779A (ko) | 폐 기능의 개선 및 방사선 유발된 폐 합병증의 예방 및/또는 치료를 위한 물질 및 방법 | |
| JP2024150531A (ja) | 吸入可能なニコチン製剤、およびその作製および使用方法 | |
| CN102078312A (zh) | 一种姜黄素类化合物干粉吸入剂及其制备方法和用途 | |
| JP2023071886A5 (enExample) | ||
| JP6316422B2 (ja) | フィンゴリモドの医薬組成物 | |
| JP7654544B2 (ja) | ベダキリンの組成物、それらを含む組み合わせ、それらを調製するための方法、それらを含む使用及び治療方法 | |
| JP2019518782A (ja) | 吸入用サーファクタント製剤 | |
| JPWO2019237028A5 (ja) | 吸入のための組成物 |